Table 1.
Effect of Treatment with Liposomal Prednisolone Phosphate, Free Prednisolone Phosphate, or Vehicle on Tumor Size and Tumor Histology. C26 B16.F10
C26 | B16.F10 | |||||||
Start | End | Start | End | |||||
C | F | L | C | F | L | |||
Tumor size (mm 3) | 16 | 59 | 48 | 15 | 14 | 163 | 136 | 17 |
Blood vessels | - | + | + | + | - | + | + | + |
Hemorrhagic area | - | - | - | - | - | ± | ± | ± |
Necrosis | - | - | - | +* | - | ±† | ±† | +* |
High cell density | - | + | + | + | ++ | ++ | ++ | ++ |
Tumor tissue was excised from C26 or B16.F10 tumor-bearing mice at the start of treatment or 3 days after a single intravenous injection with liposomal prednisolonephosphate (L), or free prednisolone phosphate (F) at a dose of 20 mg/kg, or vehicle (C). Tissue slides were evaluated regarding vascularization (CD31 staining), tumorcell density, and occurrence of necrosis and hemorrhagic areas (toluidine bluestaining).
Slides were scored as: (-) (nearly) absent; (+) present; (++) strongly present.
Predominantly in tumor core.
Infrequently observed without preferential localization.